Rony Dahan
Weizmann Institute of Science · 119 works · 3,615 citations · h-index 23
Top works
- FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
- Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis
- Type I and type II Fc receptors regulate innate and adaptive immunity
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
- Signaling by Antibodies: Recent Progress
- Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
- Single-cell genomic approaches for developing the next generation of immunotherapies
- Bispecific dendritic-T cell engager potentiates anti-tumor immunity
- Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity
- T-cell-receptor-like antibodies – generation, function and applications
- Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis
- FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
- A Promising Therapeutic Approach for Multiple Sclerosis: Recombinant T-Cell Receptor Ligands Modulate Experimental Autoimmune Encephalomyelitis by Reducing Interleukin-17 Production and Inhibiting Migration of Encephalitogenic Cells into the CNS
- Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting
- BCR affinity differentially regulates colonization of the subepithelial dome and infiltration into germinal centers within Peyer’s patches
- Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern
- Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
- HLA-DRα1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis
- A novel regulatory pathway for autoimmune disease: Binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance
- Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy